Kamada (NASDAQ:KMDA) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Kamada (NASDAQ:KMDA – Get Rating) posted its earnings results on Tuesday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.07), MarketWatch Earnings reports. Kamada had a negative net margin of 6.31% and a negative return on equity of 3.44%. During the same quarter last year, the firm earned $0.06 earnings per share. Kamada updated its FY 2022 guidance to EPS.

NASDAQ KMDA opened at $4.67 on Friday. Kamada has a 1 year low of $4.48 and a 1 year high of $6.96. The company has a fifty day simple moving average of $5.41 and a 200 day simple moving average of $5.90. The company has a quick ratio of 1.16, a current ratio of 2.75 and a debt-to-equity ratio of 0.09.

Several research firms recently issued reports on KMDA. Zacks Investment Research lowered shares of Kamada from a “buy” rating to a “hold” rating in a research note on Friday, May 6th. StockNews.com started coverage on Kamada in a research report on Friday, May 13th. They issued a “buy” rating for the company.

A number of institutional investors and hedge funds have recently made changes to their positions in KMDA. Group One Trading L.P. boosted its holdings in Kamada by 103.7% during the first quarter. Group One Trading L.P. now owns 11,064 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 307,831 shares during the period. Millennium Management LLC acquired a new position in shares of Kamada during the 2nd quarter worth about $73,000. Marshall Wace LLP bought a new stake in Kamada during the 4th quarter valued at approximately $73,000. Geode Capital Management LLC grew its holdings in Kamada by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 25,878 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,856 shares during the last quarter. Finally, Citigroup Inc. increased its position in Kamada by 2,620.0% in the 1st quarter. Citigroup Inc. now owns 36,938 shares of the biotechnology company’s stock worth $206,000 after buying an additional 35,580 shares during the period.

Kamada Company Profile (Get Rating)

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.

Further Reading